摘要
目的:探讨2型糖尿病患者(Type 2 Diabetes,T2DM)的单核细胞/高密度脂蛋白胆固醇比值(Monocyte/high Density Lipoprotein Cholesterol Ratio,MHR)与非酒精性脂肪肝(Nonalcoholic Fatty Liver Disease,NAFLD)发生风险的相关性。方法:选取2022年4月至2024年12月在江苏省原子医学研究所附属江原医院内分泌科住院的133例2型糖尿病患者,按照有无脂肪肝分为对照组(58例)和观察组(75例)。收集患者基本资料,计算MHR水平,分析两组MHR及其他指标差异。结果:与对照组相比,观察组MHR水平升高(P<0.05)。MHR与体重指数(BMI)、空腹C肽、C反应蛋白(CRP)、甘油三酯(TG)呈正相关,与高密度脂蛋白(HDL-C)呈负相关。2型糖尿病患者BMI、空腹血糖(FBG)、CRP、MHR的水平升高是发生NAFLD的独立危险因素。MHR诊断T2DM合并NAFLD的最佳截断值0.505,灵敏度为63.6%,特异性为76.3%,曲线下面积为0.768,与中性粒细胞/高密度脂蛋白胆固醇比值(Neutrophil/HDL-c Ratio,NHR)相比明显升高。结论:MHR是T2DM合并NAFLD的独立危险因素,有望成为T2DM并发NAFLD的预后评价指标。
Objective:To investigate the correlation between monocyte/high-density lipoprotein cholesterol ratio(MHR)and non-alcoholic fatty liver disease(NAFLD)in patients with type 2 diabetes mellitus(T2DM).Method(s):133 patients with type 2 diabetes admitted to Jiang Yuan Hospital Affilated to Jiangsu Institute of Nuclear Medicine from April 2022 to December 2024 were selected and divided into control group(58 cases)and observation group(75 cases)according to whether or not fatty liver was found.The basic data from patients were collected and the MHR levels were calculated to analyze the differences of MHR and other indicators between the two groups.Result(s):Compared with the control group,the level of MHR in the observation group increased(P<0.05).MHR was positively correlated with body mass index(BMI),fasting C-peptide,high-sensitivity C-reactive protein(CRP)and triglyceride(TG),and negatively correlated with high-density lipoprotein(HDL-C).The increase of BMI,fasting blood glucose(FBG),CRP and MHR were independent risk factors of T2DM complicated with NAFLD.The area under the curve of MHR in the diagnosis of T2DM complicated with NAFLD was 0.768,which was higher than the neutrophil/HDL-c ratio(NHR),the best cut-off value was 0.505,the sensitivity was 0.636 and the specificity was 0.763.Conclusion(s):High MHR is an independent risk factor for T2DM complicated with NAFLD and is expected to be a predictor of T2DM complicated with NAFLD.
作者
王珊珊
应长江
徐苏红
安秀敏
周莹
潘懿
WANG Shan-shan;YING Chang-jiang;XU Su-hong;AN Xiu-min;ZHOU Ying;PAN Yi(Department of Endocrinology,Jiang Yuan Hospital Affilated to Jiangsu Institute of Nuclear Medicine,Wuxi,Jiangsu,214063,China;Department of Endocrinology,Affilated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu,221000,China)
出处
《现代生物医学进展》
2026年第5期665-672,共8页
Progress in Modern Biomedicine
基金
江苏省卫健委重点项目(K2023063)。
